ArticleInternational journal of oncology2022
Correlation of SARS‑CoV‑2 to cancer: Carcinogenic or anticancer? (Review).
Article in International journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- SARS-CoV-2 spike protein exerts an anti-cancer effect in A549 cells in association with MEG3 and BCYRN1 regulation.Scientific reports · 2026Article
- Review
- Modulation of Patient-Derived Tumor Organoids by SARS-CoV-2 Variants Across Cancer Types: A Study Combining Morphology, Inflammation, and Whole-Exome Profiling.International journal of molecular sciences · 2026Article
- Exploiting viral infection/vaccination to focus high-affinity T cell populations into tumors using oncolytic viro-immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- From Viral Infection to Malignancy: The Dual Threat of EBV and COVID-19 in Cancer Development.Viruses · 2025Review
- Intratumoral microbiota: implications for cancer progression and treatment.Frontiers in microbiology · 2025Review
- Autopsy findings in cancer patients infected with SARS-CoV-2 show a milder presentation of COVID-19 compared to non-cancer patients.GeroScience · 2024Article
- SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization.Molecular cancer · 2024Article
- New Insights into the Link between SARS-CoV-2 Infection and Renal Cancer.Life (Basel, Switzerland) · 2023Review
- High Risk of Heart Tumors after COVID-19.Life (Basel, Switzerland) · 2023Article
- The Inflammatory Profile Correlates with COVID-19 Severity and Mortality in Cancer Patients.Journal of personalized medicine · 2023Article
- Deciphering the Relationship between SARS-CoV-2 and Cancer.International journal of molecular sciences · 2023Review
- Article
- SARS-CoV-2 and cancer: the intriguing and informative cross-talk.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022Article
- Biological effects of COVID-19 on lung cancer: Can we drive our decisions.Frontiers in oncology · 2022Review
- Bioinformatics approach to identify the influences of SARS-COV2 infections on atherosclerosis.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is highly infectious and pathogenic. Among patients with severe SARS‑CoV‑2‑caused by corona virus disease 2019 (COVID‑19), those complicated with malignant tumor are vulnerable to COVID‑19 due to compromised immune function caused by tumor depletion, malnutrition and anti‑tumor treatment. Cancer is closely related to the risk of severe illness and mortality in patients with COVID‑19. SARS‑CoV‑2 could promote tumor progression and stimulate metabolism switching in tumor cells to initiate tumor metabolic modes with higher productivity efficiency, such as glycolysis, for facilitating the massive replication of SARS‑CoV‑2. However, it has been shown that infection with SARS‑CoV‑2 leads to a delay in tumor progression of patients with natural killer cell (NK cell) lymphoma and Hodgkin's lymphoma, while SARS‑CoV‑2 elicited anti‑tumor immune response may exert a potential oncolytic role in lymphoma patients. The present review briefly summarized potential carcinogenicity and oncolytic characteristics of SARS‑CoV‑2 as well as strategies to protect patients with cancer during the COVID‑19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.